Rui Zhang

Rui Zhang is an accomplished biopharmaceutical professional currently serving as the Director at Stylus Medicine since April 2023 and as an Industry Representative for the Controlled Release Society since 2020, focusing on gene delivery and gene editing. Previously, Rui held the role of Associate Director at Tessera Therapeutics, where responsibilities included establishing a new functional area and managing a team to develop antibody-conjugated lipid nanoparticles (LNP) with successful preclinical proof of concept. As the first formulation scientist at Spark Therapeutics, Rui built the formulation team from the ground up and contributed significantly to patent filings related to novel DNA-LNPs for gene therapy and immuno-oncology applications. Rui's early career includes a postdoctoral fellowship at the University of Pennsylvania, where 300+ novel LNP formulations were designed and synthesized, and a research assistant position at the University of Missouri. Rui holds a PhD from the University of Missouri-Columbia and a Bachelor's degree from Wuhan Institute of Technology.